Prime Highlights :
- Flourish Health raised $26 million in Series A funding, led by B Capital, F-Prime and Cherryrock Capital, bringing total funding to $46 million.
- Studies with major health plans reportedly showed the model cut hospitalisations by 70% to 96% and residential treatment by 69% to 90%.
Key Facts :
- Flourish Health is a startup offering in-home mental health care for children and young adults, founded in 2022 by Natalia Birgisson, John Haskell and Josh Gachang.
- The company operates in ten US states and has grown threefold year-on-year since beginning patient care in 2023.
Background :
Mental health provider Flourish Health has raised $26 million in a Series A funding round, announced this week. B Capital, F-Prime and Cherryrock Capital led the investment, bringing the company’s total funding to $46 million since its founding in 2022.
Flourish Health offers an in-home care model for children and young adults facing serious and complex mental health needs. The company was launched by Natalia Birgisson, John Haskell and Josh Gachang. Birgisson, who serves as chief executive, said her time working in paediatric emergency rooms shaped the idea behind the startup, recalling patients who struggled to get timely support before reaching crisis point.
The company’s Care Pod teams include a psychiatrist, a licensed therapist, a patient guide and a family guide. These teams are backed by an artificial intelligence platform designed to reduce administrative work for clinicians. Families are also supported between clinical visits through school advocacy, life coaching and primary care coordination.
Flourish Health’s Director of Family Guides, Sharon Epps, said the company had seen a rise in referrals from detention centres and transitional homes, an area it had not initially expected to serve.
The company currently operates in 10 US states and has served thousands of patients, growing by 3x year-on-year since starting patient care in 2023. Executives said studies with major health plans showed the model led to sharp reductions in hospitalisations and residential treatment.
The new funding will support national expansion through partnerships with major health plans, along with further development of the company’s technology platform.
